Results 261 to 270 of about 117,235 (282)

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Lancet, The, 2022
Sanjiv J Shah, Barry A Borlaug, Donald E Cutlip   +2 more
exaly  

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

New England Journal of Medicine, 2021
Stefan D Anker, Javed Butler, Gerasimos Filippatos   +2 more
exaly  

Heart failure with a preserved ejection fraction

British Journal of Hospital Medicine, 2013
D R, Warriner, P D, Morris, K, Saraf, A, Al-Mohammad   +3 more
openaire   +2 more sources

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

New England Journal of Medicine, 2023
Javed Butler, Sanjiv J Shah, Subodh Verma   +2 more
exaly  

Heart Failure With Preserved Ejection Fraction

2021
Selma F. Mohammed, Niti R. Aggarwal, Ajith P. Nair, Anita Deswal   +3 more
openaire   +1 more source

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

Lancet, The, 2012
Burkert Pieske, Amil M Shah, Milton Packer   +2 more
exaly  

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

Lancet, The, 2003
Salim Yusuf, Karl Swedberg, Christopher B Granger   +2 more
exaly  

A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial

Lancet, The, 2016
Scott C Mckenzie, Finn Gustafsson, Filip Málek   +2 more
exaly  

Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

New England Journal of Medicine, 2008
Michel Komajda, Michael R Zile
exaly  

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

New England Journal of Medicine, 2019
Inder S Anand, Carolyn S P Lam, Aldo P Maggioni   +2 more
exaly